Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
105

Summary

Conditions
Peanut Allergy
Type
Interventional
Phase
Phase 3
Design
Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: 2:1 randomizationMasking: Triple (Participant, Care Provider, Investigator)Masking Description: Double-BlindedPrimary Purpose: Treatment

Participation Requirements

Age
Between 1 years and 3 years
Gender
Both males and females

Description

To determine the efficacy and safety of AR101 in a characterized oral desensitization immunotherapy (CODIT™) regimen compared with placebo in peanut-allergic children aged 1 to < 4 years.

To determine the efficacy and safety of AR101 in a characterized oral desensitization immunotherapy (CODIT™) regimen compared with placebo in peanut-allergic children aged 1 to < 4 years.

Tracking Information

NCT #
NCT03736447
Collaborators
Not Provided
Investigators
Study Director: Freddy Byrth Aimmune Therapeutics